Emerging therapies for pulmonary arterial hypertension (Q36821361)

16 August 2017

1 reference

title

Emerging therapies for pulmonary arterial hypertension (English)

1 reference

16 August 2017

Omar Ali

1

1 reference

16 August 2017

John Wharton

2

1 reference

16 August 2017

John Simon Russell Gibbs

3

1 reference

16 August 2017

Luke Howard

4

1 reference

16 August 2017

Martin Russell Wilkins

5

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

Expert Opinion on Investigational Drugs

16 August 2017

published in

1 reference

16 August 2017

volume

16

1 reference

16 August 2017

issue

6

1 reference

16 August 2017

page(s)

803-818

1 reference

Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Signaling molecules in nonfamilial pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

HIV-1 TAT represses transcription of the bone morphogenic protein receptor-2 in U937 monocytic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Pulmonary arterial hypertension in France: results from a national registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

The endothelin system in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Current treatment strategies for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Prostanoid therapy for pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Developmental regulation of GTP-CH1 in the porcine lung and its relationship to pulmonary vascular relaxation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Adrenomedullin: a protective factor for blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

The effects of vasoactive intestinal peptide on monocrotaline induced pulmonary hypertensive rabbits following cardiopulmonary bypass: a comparative study with isoproteronol and nitroglycerine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Role of tyrosine kinase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Reversal of experimental pulmonary hypertension by PDGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Statins and their role in vascular protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Isoprenoids as mediators of the biological effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Lovastatin stimulates human vascular smooth muscle cell expression of bone morphogenetic protein-2, a potent inhibitor of low-density lipoprotein-stimulated cell growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Attenuation of chronic hypoxic pulmonary hypertension by simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Simvastatin treatment of pulmonary hypertension: an observational case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Targeting Rho and Rho-kinase in the treatment of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Rho kinases in cardiovascular physiology and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Prostacyclin does not inhibit rho-kinase: an implication for the treatment of pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Pergolide is an inhibitor of voltage-gated potassium channels, including Kv1.5, and causes pulmonary vasoconstriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Serotonin inhibits voltage-gated K+ currents in pulmonary artery smooth muscle cells: role of 5-HT2A receptors, caveolin-1, and KV1.5 channel internalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

BMP signaling controls PASMC KV channel expression in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

O2 sensing in the human ductus arteriosus: regulation of voltage-gated K+ channels in smooth muscle cells by a mitochondrial redox sensor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Activation of K+ channels: an essential pathway in programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Contribution of the 5-HT(1B) receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT(1B)-receptor knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

5-hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT1B receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Simvastatin enhances bone morphogenetic protein receptor type II expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Transforming growth factor-beta1 induces Nox4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Signaling and functions of angiopoietin-1 in vascular protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Prednisolone inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

2-methoxyestradiol induces cell cycle arrest and mitotic cell apoptosis in human vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Cell-based gene transfer to the pulmonary vasculature: Endothelial nitric oxide synthase overexpression inhibits monocrotaline-induced pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Protective role of angiopoietin-1 in experimental pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Gene transfer of hepatocyte growth factor with prostacyclin synthase in severe pulmonary hypertension of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Repeated gene transfer of naked prostacyclin synthase plasmid into skeletal muscles attenuates monocrotaline-induced pulmonary hypertension and prolongs survival in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Inhibitor of apoptosis protein survivin regulates vascular injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Regulation of vein graft hyperplasia by survivin, an inhibitor of apoptosis protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Endothelial progenitor cells: diagnostic and therapeutic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Isolation of putative progenitor endothelial cells for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Transplantation of endothelial progenitor cells into the lung to alleviate pulmonary hypertension in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Bone marrow-derived cells contribute to pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Genetic association of the serotonin transporter in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Lack of association between angiotensin converting enzyme (ACE) genotype, serum ACE activity, and haemodynamics in patients with primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Dysfunctional Smad Signaling Contributes to Abnormal Smooth Muscle Cell Proliferation in Familial Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

BAY 41-2272, a Direct Activator of Soluble Guanylate Cyclase, Reduces Right Ventricular Hypertrophy and Prevents Pulmonary Vascular Remodeling during Chronic Hypoxia in Neonatal Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

Transgenic Mice Overexpressing the 5-Hydroxytryptamine Transporter Gene in Smooth Muscle Develop Pulmonary Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.803

10.1517/13543784.16.6.803

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference